A Phase 3 interventional study of Temozolomide and Dacarbazine in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing temozolomide in Melanoma — 2 open to participants now, 2 under way, none of them phase 3. Temozolomide · Melanoma.
Among the 50 studies testing temozolomide in Melanoma, this one has the largest enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2004, is one of 3 in phase 3, and was the 10th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →2 of the 50 studies testing temozolomide in Melanoma are open now, in 1 country. Recruiting first, the newest first:
Kari Kendra · Sites in United States
Ages 18+
Assistance Publique Hopitaux De Marseille
Ages 18+
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 37 · Phase 3 3
First in 1998; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 859 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 28 across the 46 interventional studies. Of the 40 that completed or were terminated, 19 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
42 studies in Melanoma by Merck & Co., Inc: 1 open now, 6 under way, 3 of them phase 3. Of 34 finished, 25 (74%) have results posted.
Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2004, is one of 8 in phase 3, and was the 1st registered.
Merck & Co., Inc’s Melanoma studies by the year they started, since 1996.
1 of the studies testing temozolomide in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05588453Kari KendraNatural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | 2027-04-15 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies testing temozolomide in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 42 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days ("7 days on / 7 days off" continuously)
Drug: Temozolomide
dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
Drug: Dacarbazine
oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days ("7 days on / 7 days off" continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
Also known as: Temodal, Temodar, SCH 52365
intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
Also known as: DTIC-Dome
Overall Survival
Overall Survival was defined as the time from the date of randomization to the date of death from any cause.
Time frame: The final analysis was to be performed when at least 616 deaths had occurred.
Progression Free Survival
Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.
Time frame: Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.
Objective Response Rate in Subjects With Measurable Lesions
Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.
Time frame: Treatment continued until disease progression or unacceptable toxicity.
Duration of Objective Response
Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.
Time frame: Treatment continued until disease progression or unacceptable toxicity.
| Milestone | Temozolomide | Dacarbazine |
|---|---|---|
| Started | 429 | 430 |
| Completed | 334 | 348 |
| Not completed | 95 | 82 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Subject's refusal unrelated to toxicity | 14 | 22 |
| Withdrew: Death not due to malignancy/toxicity | 1 | 3 |
| Withdrew: Medical decision unrelated toxicity/pd | 10 | 22 |
| Withdrew: Other reason | 6 | 13 |
| Withdrew: Ongoing (still on treatment) | 8 | 12 |
| Withdrew: Major protocol violation | 2 | 0 |
| Withdrew: Toxicity (related ae) | 53 | 9 |
Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.
| Months | Temozolomide | Dacarbazine |
|---|---|---|
| Progression Free Survival | 2.30 (2.23 to 2.43) | 2.17 (2.14 to 2.27) |
Overall Survival was defined as the time from the date of randomization to the date of death from any cause.
| Months | Temozolomide | Dacarbazine |
|---|---|---|
| Overall Survival | 9.13 (8.11 to 9.89) | 9.36 (8.21 to 10.28) |
Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.
| Ratio | Temozolomide | Dacarbazine |
|---|---|---|
| Objective Response Rate in Subjects With Measurable Lesions | 0.14 (0.10 to 0.17) | 0.10 (0.07 to 0.12) |
Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.
| Months | Temozolomide | Dacarbazine |
|---|---|---|
| Duration of Objective Response | 4.34 (4.17 to 6.18) | 8.31 (6.08 to 19.25) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Temozolomide | — | 124/419 (29.6%) | 394/419 (94%) |
| Dacarbazine | — | 100/421 (23.8%) | 374/421 (88.8%) |
| Event | Temozolomide | Dacarbazine |
|---|---|---|
| PLATELET COUNT DECREASEDInvestigations | 21/419 | 3/421 |
| VOMITINGGastrointestinal disorders | 15/419 | 9/421 |
| NAUSEAGastrointestinal disorders | 11/419 | 10/421 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 9/419 | 3/421 |
| ABDOMINAL PAINGastrointestinal disorders | 6/419 | 8/421 |
| PYREXIAGeneral disorders | 3/419 | 8/421 |
| FATIGUEGeneral disorders | 7/419 | 5/421 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 7/419 | 4/421 |
| HAEMOGLOBIN DECREASEDInvestigations | 3/419 | 7/421 |
| CONSTIPATIONGastrointestinal disorders | 6/419 | 2/421 |
| Event | Temozolomide | Dacarbazine |
|---|---|---|
| NAUSEAGastrointestinal disorders | 286/419 | 206/421 |
| FATIGUEGeneral disorders | 253/419 | 240/421 |
| VOMITINGGastrointestinal disorders | 211/419 | 103/421 |
| CONSTIPATIONGastrointestinal disorders | 183/419 | 111/421 |
| ANOREXIAMetabolism and nutrition disorders | 118/419 | 79/421 |
| HEADACHENervous system disorders | 92/419 | 56/421 |
| WEIGHT DECREASEDInvestigations | 87/419 | 45/421 |
| DIARRHOEAGastrointestinal disorders | 79/419 | 71/421 |
| PRURITUSSkin and subcutaneous tissue disorders | 75/419 | 29/421 |
| COUGHRespiratory, thoracic and mediastinal disorders | 71/419 | 51/421 |
| Age, Categorical(Participants) | Temozolomide | Dacarbazine | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 276 | 261 | 537 |
| >=65 years | 153 | 169 | 322 |
| Sex: Female, Male(Participants) | Temozolomide | Dacarbazine | Total |
|---|---|---|---|
| Female | 179 | 177 | 356 |
| Male | 250 | 253 | 503 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Oct 2004 to primary completion in Dec 2007, 38 months.
Results were first posted in Mar 2009, 1 year 2 months after primary completion.
Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 38 months is close to that.
Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide